- Article
- Published:
- Christine Goodchild ORCID: orcid.org/0009-0001-4787-06661,2,
- Clare Bailey1,
- Jimena Soto Hernaez3,
- Eslam Ahmed1 &
- …
- Serena Salvatore1,3
Eye (2024)Cite this article
-
28 Accesses
-
Metrics details
Subjects
- Drug therapy
- Macular degeneration
Abstract
Background
Age-related macular degeneration (AMD) remains a primary cause of blindness, with neovascular AMD (nAMD) presenting particular treatment challenges. Despite anti-vascular endothelial growth factor (anti-VEGF) therapies, many patients exhibit a suboptimal response to the previously available anti-vascular endothelial growth factor (anti-VEGF) therapies. This study evaluates the efficacy and treatment interval extension of faricimab in this patient cohort.
Methods
In a retrospective single-centre study at University Hospitals of Bristol and Weston, UK, nAMD patients suboptimally responsive to previous anti-VEGF therapies were switched to faricimab. Treatment started with an initiation phase of 4 monthly injections followed by a ‘Treat and Extend’ protocol. Outcomes included best-recorded visual acuity (BRVA), central subfield thickness (CST), the presence of retinal fluid, and treatment intervals.
Results
Among 98 eyes of 79 patients, following faricimab treatment, significant reductions in CST and retinal fluid were noted, indicating decreased disease activity. While BRVA changes were not statistically significant, the anatomical improvements suggest a potential therapeutic benefit. Notably, 40% of patients achieved extended treatment intervals, reducing the treatment burden.
Conclusion
Faricimab offers a promising alternative for nAMD patients with suboptimal responses to prior anti-VEGF treatments, demonstrating significant anatomical improvements and the possibility of extended dosing intervals. These findings highlight the need for prospective real-world studies to further assess faricimab’s role in nAMD management and its long-term impact on patient outcomes.
This is a preview of subscription content, access via your institution
Access options
Change institution
Buy or subscribe
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Learn more
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic
Article 23 March 2023
Effectiveness of bevacizumab step therapy for neovascular age-related macular degeneration
Article 20 September 2022
The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results
Article Open access 12 May 2023
Data availability
The datasets generated during and analysed during the current study are not publicly available due to reasons of sensitivity but are available from the corresponding author on reasonable request.
References
Quartilho A, Simkiss P, Zekite A, Xing W, Wormald R, Bunce C. Leading causes of certifiable visual loss in England and Wales during the year ending 31 March 2013. Eye. 2016;30:602–7.
Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng C-Y, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–e16.
Lorés-Motta L, Riaz M, Grunin M, Corominas J, van Asten F, Pauper M, et al. Association of Genetic Variants With Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration. JAMA Ophthalmol. 2018;136:875–84.
Johnston RL, Lee AY, Buckle M, Antcliff R, Bailey C, McKibbin M, et al. UK Age-Related Macular Degeneration Electronic Medical Record System (AMD EMR) Users Group Report IV: Incidence of Blindness and Sight Impairment in Ranibizumab-Treated Patients. Ophthalmology. 2016;123:2386–92.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399:729–40.
Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:Cd007419.
Monés J, Singh RP, Bandello F, Souied E, Liu X, Gale R. Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica. 2020;243:1–8.
Mehta H, Nguyen V, Barthelmes D, Pershing S, Chi GC, Dopart P, et al. Outcomes of Over 40,000 Eyes Treated for Diabetic Macula Edema in Routine Clinical Practice: A Systematic Review and Meta-analysis. Adv Ther. 2022;39:5376–90.
Yang S, Zhao J, Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des, Dev Ther. 2016;10:1857–67.
CAS Google Scholar
Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. 2023;37:3574–81.
Leung EH, Oh DJ, Alderson SE, Bracy J, McLeod M, Perez LI, et al. Initial Real-World Experience with Faricimab in Treatment-Resistant Neovascular Age-Related Macular Degeneration. Clin Ophthalmol. 2023;17:1287–93.
Funding
CG, Travel Bursary and Lecture fees from Roche Products and Santen. CB, Advisory Board, Travel Bursary, Honoraria and Lecture Fees from Bayer, Roche Products, Norvatis, Alimera Sciences, Janssen, Apellis, Boehringer-Ingelheim. SS, Advisory Board and Lecture Fees from Bayer, Roche Products and Alimera.
Author information
Authors and Affiliations
Bristol Eye Hospital, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK
Christine Goodchild,Clare Bailey,Eslam Ahmed&Serena Salvatore
Royal Victoria Eye and Ear Hospital, Adelaide Road, Dublin, Ireland
Christine Goodchild
Department of Medicine, University of Bristol, Bristol, UK
Jimena Soto Hernaez&Serena Salvatore
Authors
- Christine Goodchild
View author publications
You can also search for this author in PubMedGoogle Scholar
- Clare Bailey
View author publications
You can also search for this author in PubMedGoogle Scholar
- Jimena Soto Hernaez
View author publications
You can also search for this author in PubMedGoogle Scholar
- Eslam Ahmed
View author publications
You can also search for this author in PubMedGoogle Scholar
- Serena Salvatore
View author publications
You can also search for this author in PubMedGoogle Scholar
Contributions
CG was responsible for designing the study, conducting the search, data collection, extracting and analysing data, interpreting results, writing the manuscript, creating Tables 1 and 2 and Figs. 1 and 2, creating and updating reference lists. CB was responsible for designing the study, interpreting result, manuscript revision. JSH was responsible for data collection. ES was responsible for data collection. SS was responsible for designing the study, conducting the search, data collection, extracting and analysing data, interpreting results, writing, and revising the manuscript, tables and figures.
Corresponding author
Correspondence to Christine Goodchild.
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Goodchild, C., Bailey, C., Soto Hernaez, J. et al. Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy. Eye (2024). https://doi.org/10.1038/s41433-024-03218-7
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-024-03218-7
